Cryoport, Inc. (NASDAQ:CYRX) Shares Purchased by Arizona State Retirement System

Arizona State Retirement System raised its stake in shares of Cryoport, Inc. (NASDAQ:CYRX) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,665 shares of the company’s stock after buying an additional 696 shares during the quarter. Arizona State Retirement System’s holdings in Cryoport were worth $212,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of CYRX. Nordea Investment Management AB purchased a new position in shares of Cryoport during the 3rd quarter worth $1,153,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Cryoport by 285.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 77,409 shares of the company’s stock worth $1,061,000 after purchasing an additional 57,348 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Cryoport during the 3rd quarter worth $3,250,000. Invesco Ltd. lifted its stake in shares of Cryoport by 17.9% during the 3rd quarter. Invesco Ltd. now owns 2,062,481 shares of the company’s stock worth $28,277,000 after purchasing an additional 313,853 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Cryoport by 28.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,356,500 shares of the company’s stock worth $18,598,000 after purchasing an additional 298,995 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Stock Down 2.1 %

NASDAQ:CYRX opened at $16.13 on Monday. The company has a market capitalization of $792.95 million, a price-to-earnings ratio of -7.33 and a beta of 1.60. Cryoport, Inc. has a one year low of $9.00 and a one year high of $24.17. The stock has a 50-day simple moving average of $16.84 and a 200 day simple moving average of $14.86. The company has a debt-to-equity ratio of 0.82, a quick ratio of 11.16 and a current ratio of 11.73.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.19). The firm had revenue of $57.26 million during the quarter, compared to analyst estimates of $58.27 million. Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. Sell-side analysts predict that Cryoport, Inc. will post -1.31 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the transaction, the chief executive officer now directly owns 692,182 shares in the company, valued at $12,140,872.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the transaction, the chief executive officer now directly owns 692,182 shares in the company, valued at $12,140,872.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the transaction, the director now owns 43,187 shares of the company’s stock, valued at $633,985.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,940 shares of company stock worth $1,147,538. Corporate insiders own 10.10% of the company’s stock.

Wall Street Analysts Forecast Growth

CYRX has been the topic of several research reports. Jefferies Financial Group initiated coverage on Cryoport in a research report on Thursday, April 4th. They issued a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC cut their target price on Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. UBS Group increased their target price on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, March 15th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $17.00 target price on shares of Cryoport in a research report on Wednesday, March 13th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $18.63.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.